Figure 3 | Scientific Reports

Figure 3

From: High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma

Figure 3

The combination of navitoclax and irradiation exhibited a strong synergy regardless of the p53 mutation status. (a) The most synergistic area scores for the navitoclax–irradiation combination across 13 HNSCC cell lines. (b) A representative example of the navitoclax–irradiation combination tested on the UT-SCC-40 cell line. The dose–response matrix showing CTG viability for different dose pairs (left) and the synergy distribution plot calculated based on the ZIP synergy reference model (right) are shown. The most synergistic area score represents a synergy score calculated for the most synergistic 3 × 3 dose window (dashed rectangle).

Back to article page